Michael David Taylor - Toxicology

Author Information

Michael David Taylor is affiliated with The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children in Toronto, Ontario, Canada. His research primarily focuses on pediatric brain tumors, particularly medulloblastomas, and the development of novel therapies for these conditions.

Research Contributions

Michael David Taylor has made significant contributions to the understanding and treatment of pediatric brain tumors. His recent work includes studies on genomic predictors of response to PD-1 inhibition in children with DNA replication repair deficiencies, novel therapies for ependymomas, and amplifying natural antitumor immunity for personalized immunotherapy. He has also explored the transcriptional landscape of Shh medulloblastoma and developed clinically tractable outcome prediction models for non-WNT/non-SHH medulloblastoma based on TPD52 immunohistochemistry.

Aliases

Michael David Taylor is also known by several aliases, including Michal D. Taylor, Michael Taylor, Michael D Taylor, Michael D. Taylor, and Michael David Taylor.

Publication and Citation Metrics

Metric	Value
Total Citation Count	45,210
H-index	103
Total Paper Count	650

Publications:

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

DOI: 10.1038/s41591-021-01581-6

Year: 2022

The biology of ependymomas and emerging novel therapies.

DOI: 10.1038/s41568-021-00433-2

Year: 2022

Amplifying natural antitumor immunity for personalized immunotherapy.

DOI: 10.1038/s41422-022-00649-3

Year: 2022

The transcriptional landscape of Shh medulloblastoma

DOI: 10.1038/s41467-021-21883-0

Year: 2021

Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study

DOI: 10.1158/1078-0432.CCR-21-2057

Year: 2021

Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma

DOI: 10.1038/s41593-021-00994-3

Year: 2021

Abstract 636: PROFYLE: The pan-Canadian precision oncology program for children, adolescents and young adults with hard-to-treat cancer

DOI: 10.1158/1538-7445.AM2021-636

Year: 2021

EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY

DOI: 10.1093/neuonc/noab090.039

Year: 2021

TMOD-06. LOSS OF DICER COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE METASTATIC MEDULLOBLASTOMA

DOI: 10.1093/neuonc/noab090.147

Year: 2021

EMBR-20. ELONGATION CONTROL OF MRNA TRANSLATION DRIVES GROUP 3 MEDULLOBLASTOMA

DOI: 10.1093/neuonc/noab090.038

Year: 2021